



HAL
open science

Isavuconazole MIC distribution of 29 yeast species responsible for invasive infections (2015–2017)

M. Desnos-Ollivier, S. Bretagne, A Boullie, C. Gautier, F. Dromer, O. Lortholary

► To cite this version:

M. Desnos-Ollivier, S. Bretagne, A Boullie, C. Gautier, F. Dromer, et al.. Isavuconazole MIC distribution of 29 yeast species responsible for invasive infections (2015–2017). *Clinical Microbiology and Infection*, 2019, 25 (5), pp.634.e1-634.e4. 10.1016/j.cmi.2019.02.007 . pasteur-02192580

HAL Id: pasteur-02192580

<https://pasteur.hal.science/pasteur-02192580>

Submitted on 22 Oct 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

1 **Isavuconazole MICs distribution of 29 yeast species responsible for invasive infections**
2 **(2015-2017)**

3 Marie Desnos-Ollivier¹, Stéphane Bretagne^{1,2}, Anne Boullié¹, Cécile Gautier¹, Françoise
4 Dromer¹, Olivier Lortholary^{1,3} and the French Mycoses Study Group

5 ¹Institut Pasteur, Molecular Mycology Unit, National Reference Center for Invasive Mycoses
6 & Antifungal, UMR2000, CNRS, Paris, France

7 ² Université Paris Diderot, Laboratoire de Parasitologie-Mycologie, Hôpital Saint Louis, AP-
8 HP, Paris, France

9 ³ Université Paris Descartes, Service des Maladies Infectieuses et Tropicales, Centre
10 d'Infectiologie Necker-Pasteur, Hôpital Necker-Enfants malades, APHP, IHU Imagine,

11 Corresponding author: Olivier Lortholary, Molecular Mycology unit, Institut Pasteur, 25 rue
12 du Docteur Roux, 75774 Paris cedex 15, France; Tel: +33 1 45 68 83 55, Fax: +33 1 45 68 84
13 20; email: olivier.lortholary@pasteur.fr

14

15

16

17

18

19

20

21

22 **Abstract**

23 **Objectives**

24 Isavuconazole is a recent extended-spectrum triazole with activity against yeasts. However,
25 few data are available on the *in vitro* activity on rare yeast species. We report minimum
26 inhibitory concentration (MIC) distribution of isavuconazole compared to fluconazole for a
27 large collection of common or rare yeasts.

28 **Methods**

29 Isavuconazole and fluconazole MICs were determined using the EUCAST method for 1457
30 clinical isolates, mainly recovered from invasive infections, belonging to 29 species. They
31 were sent to the National Reference Center for Invasive Mycoses & Antifungals between
32 January 2015 and October 2017 and species identification was performed by polyphasic
33 approach (MALDI-TOF and molecular method).

34 **Results**

35 Isavuconazole had effective *in vitro* activity against *Cryptococcus neoformans*
36 (MIC₉₀<0.25mg/L), the five most common *Candida* spp. (MIC₉₀≤0.5mg/L for *Candida*
37 *albicans*, *Candida glabrata*, *Candida tropicalis*, *Candida parapsilosis* and, *Candida krusei*)
38 and also against the majority of rare species, including *Candida kefyr* and *Candida lusitaniae*.
39 A few isolates of *C. albicans* (0.7%, 3/404), *C. glabrata* (2.7%, 5/184), *C. tropicalis* (1.0%,
40 1/96) and *C. parapsilosis* (0.8%, 1/127) exhibited MIC ≥4 mg/L. All were also resistant to
41 fluconazole according to the EUCAST breakpoints. Some isolates with isavuconazole MIC
42 ≥4 mg/L were also observed among rarer species: *Meyerozyma guilliermondii* (8.7%, 2/23),
43 *Wickerhamomyces anomalus* (10.0%, 1/10). Other rare species *Saprochaete clavata*,
44 *Magnusiomyces capitatus* and *Rhodotorula mucilaginosa* had high MIC₅₀ (≥1mg/L) and
45 MIC₉₀ (≥4mg/L) and could be considered as resistant to isavuconazole.

46 **Conclusions**

47 We confirmed the good *in vitro* activity of isavuconazole against common *Candida*,
48 *Cryptococcus* species and majority of the rare yeast species studied.

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72 **Introduction**

73 Isavuconazole is part of the triazoles antifungal agents which exert antifungal activity through
74 the inhibition of sterol 14- α -demethylase. It is currently approved as one of the first line
75 therapy for human invasive aspergillosis and mucormycosis (1-4). *In vitro* activity of
76 isavuconazole against *Cryptococcus* spp. is also reported (5) and a prospective clinical trial
77 enrolling patients with candidemia or invasive candidiasis failed to demonstrate the non-
78 inferiority with caspofungin (6). *In vitro*, isavuconazole is active against common *Candida*
79 species with higher MIC value for *Candida glabrata* and *Candida krusei* than for *Candida*
80 *albicans* (7-9). Few data are available for rare yeast species.

81 We here reported minimal inhibitory concentrations (MICs) of isavuconazole using EUCAST
82 method for a large collection of yeast species recovered mainly from blood culture during a
83 prospective multicenter surveillance program. We compared the results with those of
84 fluconazole for which breakpoints (BP) exist for several *Candida* species and given that
85 fluconazole is one of the first option for treating invasive yeast infections. The objective was
86 to know whether isavuconazole could be proposed as an option for also treating yeast
87 infection in case of concomitant mold infection, justifying using an extended spectrum azole.

88 **Methods**

89 **Isolates and species identification**

90 As part of its missions of expertise and surveillance, the National Reference Center for
91 Invasive Mycoses & Antifungals (NRCMA) received clinical isolates involved in invasive
92 infections from hospitals in France. Yeast isolates received between January 2015 and
93 October 2017 were checked for purity on chromogenic medium BBL Chromagar™ *Candida*
94 (BD) or Niger seed medium for *Cryptococcus* species and identified at the species level by
95 phenotypic method and mass spectrometry (MALDI-TOF, Bruker Biotyper, Bruker Daltonic,
96 Germany). For *C. albicans* and *Candida dubliniensis*, a duplex PCR was performed (10). For

97 rare species, D1D2 and ITS regions of ribosomal DNA were amplified and sequenced with
98 panfungal primers (NL1/NL4 and V9D/LS266, respectively). In addition, actin gene (for
99 *Candida lusitanae*), *RPBI* gene (for *Meyerozyma guilliermondii*, *Meyerozyma caribbica*,
100 primer forward 5'-AGGGTTTGCGAGTGTGTTTGT-3', primer reverse 5'-
101 CGTCAAGCTCCAATCTCTGC-3') and IGS1 region (for *Trichosporon* spp.) were
102 sequenced (11). *Cryptococcus neoformans* serotypes were determined by amplification of
103 *PAK1* and *GPA1* genes with serotype-specific primers and ploidy by flow cytometry (12).

104 **Minimal Inhibitory Concentration (MIC) determination**

105 Isavuconazole and fluconazole MICs were determined in parallel according to the EUCAST
106 standardized broth microdilution method (13). The concentrations tested ranged between
107 0.007 mg/L to 4 mg/L and between 0.125 mg/L to 64 mg/L for isavuconazole and
108 fluconazole, respectively. For MIC determination, tissue culture testplate with F-bottom,
109 sterilized by radiation, were used (TPP®, Switzerland, Ref 92096). Quality control strains
110 (ATCC22019, ATCC6258) were included in each set. The concentrations that inhibited 50%
111 (MIC₅₀) and 90% (MIC₉₀) of the isolates were determined for isavuconazole and
112 fluconazole for each species represented by at least 10 isolates. Results were analysed using
113 EUCAST BP (resistance when MIC >4mg/L for *C. albicans*, *Candida tropicalis*, *Candida*
114 *parapsilosis* >32mg/L for *C. glabrata*) (14). Rare species without defined BP and exhibiting
115 fluconazole MIC₅₀>4mg/L (non-species related BP determined by EUCAST is R>4mg/L)
116 were considered as intrinsically resistant to fluconazole or at least less susceptible.

117 **Results**

118 The 1457 isolates analysed belonged to 29 species (23 ascomycetous and 6 basidiomycetous)
119 including the five most frequent species involved in candidemia (*C. albicans*, *C. glabrata*, *C.*
120 *tropicalis*, *C. parapsilosis*, and *C. krusei*) and three serotypes of *Cryptococcus neoformans*
121 (Table 1). Isolates were mostly (93%, 1351/1457) recovered from blood cultures (n=1133),

122 cerebrospinal fluids (n=89) or other site of invasive infections (n=129). Isolates were sent
123 mainly (52.5%, 765/1457) in the context of the active surveillance of all yeasts fungemia in
124 the Paris area (YEASTS program). Other isolates were sent in the context of the French
125 Surveillance Network of Invasive Fungal Infections (RESSIF) but only in case of abnormal
126 antifungal susceptibility profiles and/or rare species.

127 For 17 species among the 29 studied here, isavuconazole MIC₉₀ varied between <0.007 and 2
128 mg/L with 14/17 having an MIC₉₀ <0.5 mg/L. Of note, *C. neoformans* serotype D exhibited
129 lower MIC₅₀ and MIC₉₀ for isavuconazole and fluconazole than serotype A and hybrid AD
130 isolates. Three species exhibited an MIC₉₀ of 0.5 mg/L (*C. glabrata*, *Saccharomyces*
131 *cerevisiae*) and 2 mg/L (*Meyerozyma guilliermondii*). Finally, *Saprochaete clavata*,
132 *Magnusiomyces capitatus* and *Rhodotorula mucilaginosa* had high MIC₉₀ (≥ 4 mg/L).

133 MICs were also determined for 9 rare yeast species (7 Ascomycetous and 2 Basidiomycetous)
134 (Table 1) for which less than ten isolates were studied. For four species, the MIC values were
135 low (<0.25mg/L) whereas MIC distribution was heterogeneous for the others (Table S1).

136 Analysis of the MIC distributions showed that for 11 species, some isolates (2.5%-10.0%) had
137 a MIC above the MIC₉₀ (Table 1 and Table S1). Of those with MICs ≥ 4 mg/L were found
138 isolates of *C. albicans* (n=3), *C. glabrata* (n=5), *C. tropicalis* (n=1), *C. parapsilosis* (n=1), *M.*
139 *guilliermondii* (n=2), and *Wickerhamomyces anomalus* (n=1). All these isolates were
140 considered resistant to fluconazole according to the EUCAST BP.

141 In the absence of BP and epidemiological cut-off values defined for isavuconazole, Astvad *et*
142 *al* (17) categorized isolates as wild-type (wt) and non-wild-type (non-wt) based on a wild-type
143 upper limit value (wtUL). The wtUL corresponds to two dilutions above the MIC₅₀, or to the
144 lowest concentration tested in case all the isolates of a given species exhibit MICs less than or
145 equal to the lowest concentration tested (*C. dubliniensis* in our study). In case of species
146 exhibiting an MIC₅₀ equal to the highest concentration tested (*S. clavata* and *M. capitatus* in

147 our study), the wtUL is impossible to determine. Comparable to the published wtUL values,
148 only minor differences (maximum two-fold dilutions) were detected here for some species.
149 The percentage of isolates with MIC>wtUL ranged from 1.3% to 5.2% for common *Candida*
150 species, a proportion similar to that of the fluconazole-resistant isolates (2.72% to 6.3%, Table
151 1). This proportion ranged between 0 and 13% for rare species, except for *S. cerevisiae* that
152 reached almost 44% (7/16) of non-wt with a very heterogeneous MIC distribution (Table S1).
153 Looking at cross-resistance (9), among the 12 non-wt isolates of *C. albicans*, 11 were resistant
154 to fluconazole (MIC>4mg/L). For the 5 non-wt isolates of *C. tropicalis*, 3 were resistant to
155 fluconazole (MIC>4mg/L). All the 6 non-wt isolates of *C. parapsilosis* and the 7 non-wt
156 isolates of *C. glabrata* were also resistant to fluconazole (MIC>4mg/L and MIC>32mg/L,
157 respectively). Similarly, all isolates of *C. albicans* (11/404, 2.7%) resistant to fluconazole
158 were non-wt for isavuconazole. For *C. glabrata* (11/184, 5.9%), *C. tropicalis* (3/96, 3.1%)
159 and *C. parapsilosis* (8/127, 6.3%) resistant to fluconazole, the majority (7/11, 2/3 and 6/8,
160 respectively) were non-wt for isavuconazole.

161 **Discussion**

162 We here confirmed that isavuconazole is active *in vitro* against *C. neoformans* and the most
163 common *Candida* species (7, 8). Of note, *C. glabrata* and *C. krusei* which are considered as
164 less susceptible or intrinsically resistant to fluconazole, respectively, had isavuconazole
165 MIC₉₀≤0.5 mg/L which is higher than for *C. albicans* but suggest a good *in vitro* activity (7,
166 9). We also observed a low percentage of isolates of common *Candida* species categorized as
167 fluconazole resistant or with high MIC for isavuconazole. But mainly, isolates resistant to
168 fluconazole were also nonwt for isavuconazole. The proportion of isavuconazole non-wt
169 isolates was comparable to that obtained by Marcos-Zambrano *et al.* for *C. albicans* [2.97%
170 (12/404) vs. 2.3%] but higher for *C. glabrata* [3.8% (7/184) vs. 1.1%], *C. parapsilosis* [4.7%
171 (6/127) vs. 1.5%] and *C. tropicalis* [5.2% (5/96) vs. 0%] (19). Our data suggest that

172 isavuconazole is also active *in vitro* against the majority of rare yeast species studied, except
173 for species already considered as intrinsically resistant to fluconazole such as *S. cerevisiae*, *M.*
174 *guilliermondii*, *S. clavata*, *M. capitatus* and *R. mucilaginosa* (11, 15, 16). These results are in
175 accordance with data reviewed by Miceli *et al.* and Astvad *et al.*, except for *M. capitatus* and
176 *R. mucilaginosa* previously reported with low MICs (17, 18). In conclusion, except for *C.*
177 *krusei*, MIC distributions of isavuconazole and fluconazole were comparable for common and
178 rare yeast species. .

179 Preliminary results were presented at the 28th European Congress of Clinical Microbiology
180 and Infectious Diseases, (21-24 April 2018, Madrid, Spain; abstract number 7965).

181 **Conflict of interests**

182 SB: consultancy (Gilead), honorarium for educational programs (Astellas), congress
183 symposium (Gilead, Bio-Rad), and travel grants (Pfizer).

184 OL: member of speaker's bureau Merck, Pfizer, Astellas, Gilead; consultant for Gilead

185 MDO, AB, CG and FD: nothing to declare

186 **Funding**

187 Supported by Santé Publique France and Institut Pasteur. The funders had no role in study
188 design, data collection, analysis or interpretation of data.

189 **Acknowledgments**

190 The following investigators are members of the French Mycoses Study Group: N. Brieu (Aix
191 en Provence), T. Chouaki (Amiens), M. Pihet (Angers), S. Bland (Annecy), V. Blanc
192 (Antibes), A. P. Bellanger, F. Grenouillet, L. Millon (Besançon), S. Brun (Bobigny), I.
193 Poilane (Bondy), F. Gabriel (Bordeaux), A. L. Roux (Boulogne Billancourt), D. Quinio, E.
194 Moalic (Brest), J. Bonhomme (Caen), P. Poirier, C. Nourrisson (Clermont Ferrand), F.

195 Botterel, N. Ait-Ammar (hôpital Henri Mondor, Créteil), N. Fauchet (Centre Intercommunal,
196 Créteil), E. Forget (Clichy), F. Dalle (Dijon), P. Cahen (Foch), C. Lawrence (Garches), O.
197 Faure, D. Maubon, M. Cornet (Grenoble), M. Nicolas (Guadeloupe), M. Demar, C. Nabet
198 (Guyane), A. Angoulvant (Kremlin-Bicêtre), S. Picot, N. Traversier (La Réunion), O. Eloy
199 (Le Chesnay), B. Sendid (Lille), B. Bouteille (Limoges), F. Persat, M. Wallon (Lyon), S.
200 Ranque, H. Piarroux (Marseille), N. Desbois (Fort de France, Martinique), L. Collet
201 (Mayotte), N. Bourgeois (Montpellier), F. Moriot (Nantes), O. Mouquet (Nevers), L.
202 Hasseine, M. Gari-Toussaint (Nice), M. Sasso (Nimes), D. Poisson (Orléans), A. Minoza, C.
203 Kauffman (Poitiers), D. Toubas (Reims), J. P. Gangneux (Rennes), L. Favennec (Rouen), N.
204 Godineau (St Denis), H. Raberin (St Etienne), V. Bru (Strasbourg), S. Cassaing (Toulouse),
205 E. Bailly (Tours), E. Chachaty (Villejuif), and in Paris: C. Bonnal (hôpital Bichat), A. Paugam
206 (hôpital Cochin), B. Heym (hôpital de la Croix St Simon), M.-E. Bougnoux, E. Sitterlé
207 (hôpital Necker), A. Alanio (hôpital Saint Louis), D. Moissenet (hôpital Trousseau), S.
208 Bonacorsi, P. Mariani (hôpital Robert Debré).

209 **References**

210 [1]Tissot F, Agrawal S, Pagano L, Petrikkos G, Groll AH, Skiada A, et al. ECIL-6 guidelines
211 for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and
212 hematopoietic stem cell transplant patients. *Haematologica* 2017;102(3):433-44.
213 [2]Ullmann AJ, Aguado JM, Arikan-Akdagli S, Denning DW, Groll AH, Lagrou K, et al.
214 Diagnosis and management of *Aspergillus* diseases: executive summary of the 2017
215 ESCMID-ECMM-ERS guideline. *Clinical microbiology and infection : the official*
216 *publication of the European Society of Clinical Microbiology and Infectious Diseases*
217 2018;24 Suppl 1:e1-e38.
218 [3][http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002734/
219 human_med_001907.jsp&mid=WC0b01ac058001d124](http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002734/human_med_001907.jsp&mid=WC0b01ac058001d124).

220 [4]http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207500Orig1s000lbl.pdf; ,
221 (2015).

222 [5]Thompson GR, 3rd, Rendon A, Ribeiro Dos Santos R, Queiroz-Telles F, Ostrosky-
223 Zeichner L, Azie N, et al. Isavuconazole Treatment of Cryptococcosis and Dimorphic
224 Mycoses. *Clinical infectious diseases : an official publication of the Infectious Diseases*
225 *Society of America* 2016;63(3):356-62.

226 [6]Kullberg BJ, Thompson GR, 3rd, Pappas PG, Vazquez JA, Viscoli C, Ostrosky-Zeichner
227 L, et al., editors. Isavuconazole versus caspofungin in the treatment of candidaemia and other
228 invasive *Candida* infections: the ACTIVE trial. 26th European Congress of Clinical
229 Microbiology and Infectious Diseases; 2016; Amsterdam, Netherlands.

230 [7]Howard SJ, Lass-Florl C, Cuenca-Estrella M, Gomez-Lopez A, Arendrup MC.
231 Determination of isavuconazole susceptibility of *Aspergillus* and *Candida* species by the
232 EUCAST method. *Antimicrobial agents and chemotherapy* 2013;57(11):5426-31.

233 [8]Schmitt-Hoffmann A, Roos B, Heep M, Schleimer M, Weidekamm E, Brown T, et al.
234 Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal
235 triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral
236 administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy
237 volunteers. *Antimicrobial agents and chemotherapy* 2006;50(1):279-85.

238 [9]Castanheira M, Messer SA, Rhomberg PR, Dietrich RR, Jones RN, Pfaller MA.
239 Isavuconazole and nine comparator antifungal susceptibility profiles for common and
240 uncommon *Candida* species collected in 2012: application of new CLSI clinical breakpoints
241 and epidemiological cutoff values. *Mycopathologia* 2014;178(1-2):1-9.

242 [10]Donnelly SM, Sullivan DJ, Shanley DB, Coleman DC. Phylogenetic analysis and rapid
243 identification of *Candida dubliniensis* based on analysis of ACT1 intron and exon sequences.
244 *Microbiology* 1999;145 ((Pt 8)):1871-82.

245 [11]Bretagne S, Renaudat C, Desnos-Ollivier M, Sitbon K, Lortholary O, Dromer F, et al.
246 Predisposing factors and outcome of uncommon yeast species-related fungaemia based on an
247 exhaustive surveillance programme (2002-14). *The Journal of antimicrobial chemotherapy*
248 2017;72(6):1784-93.

249 [12]Lengeler KB, Cox GM, Heitman J. Serotype AD strains of *Cryptococcus neoformans* are
250 diploid or aneuploid and are heterozygous at the mating-type locus. *Infection and immunity*
251 2001;69(1):115-22.

252 [13]Arendrup MC, Cuenca-Estrella M, Lass-Florl C, Hope W, Eucast A. EUCAST technical
253 note on the EUCAST definitive document EDef 7.2: method for the determination of broth
254 dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2
255 (EUCAST-AFST). *Clinical microbiology and infection : the official publication of the*
256 *European Society of Clinical Microbiology and Infectious Diseases* 2012;18(7):E246-7.

257 [14]Testing TECoAS. Antifungal Agents Breakpoint tables for interpretation of MICs 2018.
258 Available from:
259 [http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/AFST/Clinical_breakpoints/](http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/AFST/Clinical_breakpoints/Antifungal_breakpoints_v_9.0_180212.pdf)
260 [Antifungal_breakpoints_v_9.0_180212.pdf](http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/AFST/Clinical_breakpoints/Antifungal_breakpoints_v_9.0_180212.pdf)

261 [15]Arendrup MC, Patterson TF. Multidrug-Resistant *Candida*: Epidemiology, Molecular
262 Mechanisms, and Treatment. *The Journal of infectious diseases* 2017;216(suppl_3):S445-S51.

263 [16]Nunes JM, Bizerra FC, Ferreira RC, Colombo AL. Molecular identification, antifungal
264 susceptibility profile, and biofilm formation of clinical and environmental *Rhodotorula*
265 species isolates. *Antimicrobial agents and chemotherapy* 2013;57(1):382-9.

266 [17]Astvad KMT, Hare RK, Arendrup MC. Evaluation of the in vitro activity of
267 isavuconazole and comparator voriconazole against 2635 contemporary clinical *Candida* and
268 *Aspergillus* isolates. *Clinical microbiology and infection : the official publication of the*
269 *European Society of Clinical Microbiology and Infectious Diseases* 2017;23(11):882-7.

270 [18]Miceli MH, Kauffman CA. Isavuconazole: A New Broad-Spectrum Triazole Antifungal
271 Agent. *Clinical infectious diseases : an official publication of the Infectious Diseases Society*
272 *of America* 2015;61(10):1558-65.

273 [19]Marcos-Zambrano LJ, Gomez A, Sanchez-Carrillo C, Bouza E, Munoz P, Escibano P, et
274 al. Isavuconazole is highly active in vitro against *Candida* species isolates but shows trailing
275 effect. *Clinical microbiology and infection : the official publication of the European Society*
276 *of Clinical Microbiology and Infectious Diseases* 2018.

277

Table 1: Isavuconazole and Fluconazole susceptibility of the 20 yeast species with more than 10 isolates studied (France, 2015-2017)

Species (current name)	n	% of isolates from blood culture or CSF (nb of isolates)	Isavuconazole						Fluconazole			
			MIC50 (mg/L)	MIC90 (mg/L)	MIC range (mg/L)	% isolates with MIC > MIC90 (nb of isolates)	wtUL (mg/L)	% isolates with MIC>wtUL (nb of isolates)	MIC50 (mg/L)	MIC90 (mg/L)	MIC range (mg/L)	% of isolates Resistant*(nb of isolates)
<i>Candida albicans</i>	404	91.8% (371)	≤0.007	≤0.007	≤0.007-≥4	4.95 (20)	0.03	2.97 (12)	≤0.125	0.25	≤0.125 -≥64	2.72 (11)
<i>Candida dubliniensis</i>	34	97.1 (33)	≤0.007	≤0.007	≤0.007-≤0.007	0 (0)	≤0.007	0	≤0.125	0.25	≤0.125 -0.5	NA
<i>Candida tropicalis</i>	96	89.6% (86)	≤0.007	0.03	≤0.007-≥4	5.21 (5)	0.03	5.21 (5)	0.25	1	≤0.125 -≥64	3.16 (2)
<i>Candida parapsilosis</i>	127	85.8% (109)	0.015	0.03	≤0.007-≥4	5.51 (7)	0.06	4.72 (6)	0.5	2	≤0.125 -≥64	6.3 (8)
<i>Candida orthopsilosis</i>	10	100% (10)	0.015	0.06	≤0.007-0.25	10 (1)	0.06	10.0 (1)	0.5	16	0.25 - 16	20 (2)
<i>Candida metapsilosis</i>	11	72.7% (8)	0.015	0.015	≤0.007-0.015	0 (0)	0.06	0	1	1	1 - 2	0
<i>Candida glabrata</i>	184	91.3% (168)	0.25	0.5	0.03-≥4	7.07 (13)	1	3.80 (7)	8	16	1 - ≥64	5.98 (11)
<i>Saccharomyces cerevisiae</i>	16	100% (16)	≤0.007	0.5	0.03-0.5	0 (0)	0.03	43.75 (7)	8	32	≤0.125 -32	56.25 (9)
<i>Candida lusitanae</i> (<i>Clavispora lusitanae</i>)	55	96.4% (53)	≤0.007	0.015	≤0.007-0.5	5.45 (3)	0.03	3.64 (2)	0.25	0.5	≤0.125 -16	3.64 (2)
<i>Candida guilliermondii</i> (<i>Meyerozyma guilliermondii</i>)	23	91.3% (21)	0.25	2	0.03-≥4	8.7 (2)	1	13.04 (3)	4	16	1 -≥64	NA
<i>Candida krusei</i> (<i>Pichia kudriavzevii</i>)	76	90.8% (69)	0.125	0.25	0.015-1	6.58 (5)	0.5	1.32 (1)	32	64	16 -≥64	NA
<i>Candida kefyr</i> (<i>Kluyveromyces marxianus</i>)	41	80.5%(33)	≤0.007	≤0.007	≤0.007-0.015	4.88 (2)	0.03	0	0.25	0.5	≤0.125 -1	0
<i>Candida pelliculosa</i> (<i>Wickerhamomyces anomalus</i>)	10	60% (6)	0.06	0.06	0.03-4	10 (1)	0.25	10.0 (1)	2	4	1-8	20 (2)
<i>Pichia ohmeri</i> (<i>Kodamaea ohmeri</i>)	11	100%(11)	0.015	0.03	≤0.007-0.25	9.09 (1)	0.06	9.09 (1)	4	4	2-64	9.09 (1)
<i>Geotrichum clavatum</i> (<i>Saprochaete clavata</i>)	64	45.3%(29)	4	≥4	0.25-≥4	0 (0)	NA	NA	16	32	0.25-32	81.25 (52)
<i>Geotrichum capitatum</i> (<i>Magnusiomyces capitatus</i>)	25	48% (12)	4	≥4	0.125-≥4	0 (0)	NA	NA	4	16	0.25-32	48 (12)
<i>Cryptococcus neoformans</i> var. <i>grubii</i> (A)	158	70.9% (112)	0.06	0.25	≤0.007-0.5	2.53 (4)	0.25	2.53 (4)	2	8	≤0.125 -16	11.39 (18)
<i>Cryptococcus neoformans</i> var. <i>neoformans</i> (D)	25	60% (15)	0.015	0.03	≤0.007-0.125	8 (2)	0.06	4.0 (1)	1	2	0.25-2	0
<i>Cryptococcus neoformans</i> AD hybrid	26	73.1% (19)	0.03	0.125	≤0.007-0.25	7.69 (2)	0.125	7.69 (2)	2	8	≤0.125 -16	15.38 (4)
<i>Rhodotorula mucilaginosa</i>	16	93.8% (15)	1	4	0.125-4	0 (0)	4	25.0 (4)	≥64	≥64	1-≥64	93.75 (15)
<i>Candida auris</i>	2	50% (1)	NA	NA	0.015	NA	NA	NA	NA	NA	16-64	100 (2)
<i>Candida inconspicua</i>	8	75%(6)	0.06	NA	0.06-0.25	NA	NA	NA	16	NA	4-32	87.5 (7)
<i>Candida nivariensis</i>	3	100%(3)	NA	NA	≤0.007-0.5	NA	NA	NA	NA	NA	2-4	0
<i>Candida utilis</i> (<i>Cyberlindnera jadinii</i>)	5	80%(4)	0.03	NA	0.015-0.03	NA	NA	NA	1	NA	1-2	0
<i>Geotrichum candidum</i> (<i>Galactomyces candidus</i>)	7	0% (0)	0.25	NA	≤0.007-2	NA	NA	NA	16	NA	0.5-≥64	85.71 (6)
<i>Candida fermentati</i> (<i>Meyerozyma caribbica</i>)	3	66.7%(2)	NA	NA	0.06-≥ 4	NA	NA	NA	NA	NA	4-≥64	66.67 (2)
<i>Yarrowia lipolytica</i>	5	40% (2)	0.125	NA	0.125-0.25	NA	NA	NA	2	NA	≤0.124-16	20 (1)
<i>Trichosporon asahii</i>	9	66.7% (6)	0.25	NA	0.06-1	NA	NA	NA	2	NA	0.25-8	11.11 (1)
<i>Trichosporon dermatis</i> (<i>Cutaneotrichosporon dermatis</i>)	3	66.7%(2)	NA	NA	0.06-2	NA	NA	NA	NA	NA	2-4	0

*EUCAST BP were used for categorized isolates as resistant. Non-species related BP (R>4mg/L) was used for all species without any BP.